Genetic Variations Related to Angiotensin II Production and Risk for Basal Cell Carcinoma

• Published in: Biochemical genetics
• Main Authors: Gintoni, Iphigenia, Mastrogeorgiou, Michael, Papakosta, Veronica, Vassiliou, Stavros, Yapijakis, Christos
• Format: Journal Article
• Language: English
• Published: United States 28.03.2024
• Subjects: Angiotensinogen; BCC; Renin-angiotensin system; Angiotensin; DNA polymorphism; Skin cancer
• DOI: 10.1007/s10528-024-10746-0
• ISSN: 0006-2928

Basal cell carcinoma (BCC) is the most prevalent human neoplasm, with constantly increasing annual incidence. Despite its slow growth, BCC is locally invasive and, if left untreated, can cause severe complications, including metastasis and death. The renin-angiotensin system (RAS) plays a key role in electrolyte balance, atrial pressure, tissue development, homeostasis, and inflammation, but also in cancer development. After binding to its type 1 receptor (AT1R), angiotensin II (ANGII), the system's principal hormonal effector, regulates cancer pathways spanning from the formation of the initial cancer cell to the construction and nutrition of the tumor microenvironment, angiogenesis, proliferation, and metastasis. Although the role of RAS in the development of skin pathologies has not been widely researched, RAS-targeting antihypertensive medications have been shown to have a chemoprotective effect against BCC. Based on those findings, our group conducted a series of genetic association studies to investigate the association between common functional variations in key genes related to ANGII production (AGT, ACE, ACE2, AT1R, AT2R, and CMA1) and the risk of BCC occurrence. This review provides a summary of the current understanding of the ANGII involvement in BCC development. The reliable and easily assessed pool of genetic biomarkers may be used for predictive testing and prevention purposes in high-risk individuals.